What question did this study set out to answer?

This study aims to compare mortality trends of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in the U.S. population over 24 years.

May 30, 2026

Comparative analysis of mortality trends in acute versus chronic myeloid leukemia in the U.S. population with time series projection: A CDC WONDER–based study (1999–2023).

Key Points

This study aims to compare mortality trends of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in the U.S. population over 24 years.
Data retrieved from the CDC WONDER database covering individuals aged ≥45 years (1999-2023).
Used joinpoint regression to analyze age-adjusted mortality rates and estimate annual percent changes with 95% CI.
Employed an ARIMA model for future mortality projections through 2030.
207,992 deaths due to AML (AAMR: 6.87) and 27,199 deaths due to CML (AAMR: 0.93) from 1999 to 2023.
Males had higher mortality rates for both leukemias, with significant upward trends in AML mortality for males (APC: 5.66) and non-Hispanics (APC: 4.91).
ARIMA projections indicate stable AML rates around 6.68 with CML rates declining from 0.71 to 0.57 by 2030, suggesting persistent disparities.

Abstract

e18501 Background: Myeloid leukemias (ML) pose a significant public health concern globally and in the United States, particularly affecting older adults. Acute (AML) and chronic (CML) forms differ in clinical behavior and outcomes. This study compares mortality trends of AML and CML among the U.S. population from 1999 to 2023 and uses an autoregressive integrated moving average (ARIMA) model for predicting future trends. Methods: Data retrieved from the CDC WONDER database (1999-2023) included individuals aged ≥45 years. Mortality trends among people diagnosed with AML (C92.0) and CML (C92.1) individually were analyzed. We performed a head-to-head comparison of both groups. Age-adjusted mortality rates (AAMRs) per 100,000 population stratified by age, sex, race, Hispanic origin, U.S. Census regions, and 2013 urbanization categories were analyzed. Joinpoint regression was used to estimate Annual Percent Changes (APCs) and corresponding 95% CI. p < 0.05 was considered significant. R Software (Version 4.5.0) was used for time-series projections performed using an ARIMA model based on historical trends. Results: Between 1999-2023, a total of 207,992 deaths were attributed to AML (AAMR: 6.87) while CML accounted for 27,199 deaths (AAMR: 0.93). In both AML and CML, males showed higher mortality rates than females contributing to 56.9% and 55.4% of total deaths respectively. From 1999 to 2001, males and non-Hispanics showed significant upward trends in AML mortality with APC of 5.66 (95% CI: 2.09-8.78) and 4.91 (95% CI: 2.13-7.11), respectively. While in CML, from 1999-2006 males and non-Hispanics showed a notable decline in mortality with APC of -9.23 (95% CI: -11.22 - -7.77) and -9.22 (95% CI: -12.81 - -7.15), respectively. Whites affected by AML exhibited significant rising trends in mortality from 1999-2010 with APC of 2.14 (95% CI: 0.84-7.21). For AML, the Northeast region reported the highest AAMR 6.90 whereas for CML, the highest AAMR (1.0) was observed in the Midwest. Among states, North Dakota showed the highest AAMR of 8.8 in AML-group while Wyoming recorded the highest AAMR for CML at 1.2. ARIMA-based forecasting through 2030 showed relatively stable AML rates at approximately 6.68 (95% prediction interval: 6.09–7.28), whereas CML rates declined from 0.71 to 0.57 with wider uncertainty (95% prediction interval in 2030: −0.17 to 1.32), highlighting persistent disparities. Conclusions: AML mortality rose sharply, then steadily increased before declining, whereas CML mortality fell rapidly and later plateaued. These distinct trends indicates the need for population specific interventions and evaluation of therapeutic strategies.

Mark Helpful

Bookmark

Relay